Phosphonate O-deethylation of [4-(4-bromo-2-cyano-phenylcarbamoyl) benzyl]-phosphonic acid diethyl ester, a lipoprotein lipase-promoting agent, catalyzed by cytochrome P450 2C8 and 3A4 in human liver microsomes

Drug Metabolism and Disposition

Volumn 30, Issue 3, 2002, Pages 301-306

  Morioka, Yujiro ^a   Otsu, Makiko ^b   Naito, Shinsaku ^a   Imai, Teruko ^b  

^a Naruto Research Institute   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; ESTER DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER METABOLISM; LIVER MICROSOME; LYMPHOBLASTOID CELL; METABOLIC ACTIVATION; PRIORITY JOURNAL; VIRUS EXPRESSION; VIRUS INFECTION;

ANTILIPEMIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; HUMANS; LIPOPROTEIN LIPASE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RECOMBINANT PROTEINS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 0036183479     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.3.301     Document Type: Article

References (38)

1. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
2. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
3. Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits
4. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9
5. The Drosophila cytochrome P450 gene Cyp6a2: Structure, localization, heterologous expression, and induction by phenobarbital
6. Tissue fraction studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue
7. High density lipoprotein metabolism
8. Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modification, purification, spectral characterization, reconstitution conditions and catalytic activities
9. Biochemistry and molecular biology of the human CYP2C subfamily
10. Evidence that CYP2C19 is the major S(+)-mephenytoin 4′-hydroxylase in humans
11. High-density lipoprotein-the clinical implications of recent studies
12. Human cytochrome P450 enzymes
13. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations
14. Metabolism of retinoic acid by human liver cytochrome P450IIC8
15. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9
16. Heterologous expression and kinetic characterization of human cytochromes P-450: Validation of a pharmaceutical tool for drug metabolism research
17. Metabolism of diethyl 4-[(4-bromo-2-cyanophenyl)-carbamoyl] benzyl-phosphonate in the rat
18. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
19. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes
20. Pharmacokinetic drug interactions of macrolides
21. Cyclosporin A drug interaction. Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
22. Selective biotransformation of Taxol to 6-hydroxytaxol by human cytochrome P450 2C8
23. Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics
24. The mammalian carboxylesterases: From molecules to functions
25. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man
26. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
27. Metabolism in vitro of tris(2,3-dibromopropyl)-phosphate: Oxidative debromination and bis(2,3-dibromopropyl) phosphate formation as correlates of mutagenicity and covalent protein binding
28. Mutagenic activation of tris(2,3-dibromopropyl) phosphate: The role of microsomal oxidative metabolism
29. Detoxication of paraoxon by rat liver homogenate and serum carboxylesterases and A-esterases
30. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atheroscterosis
31. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886 a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats
32. The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesterol ester transfer protein activity
33. Esterases: Problems of identification and classification
34. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides
35. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
36. A pharmacokinetic analysis program (MULTI) for microcomputer
37. 5 in stimulation of catalytic activities of cytochrome P450 3A4/ NADPH-cytochrome P450 reductase system and studies with apocytochrome b5
38. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes